Rising Kick influencer Clavicular has found himself at the center of another controversy, this time regarding his open discussion of pharma interventions for aesthetic improvement. During a recent appearance on The Adam Friedland Show, the 20-year-old internet personality clarified his stance on GLP-1 treatments.
When asked about his daily routine, Clavicular detailed a comprehensive regimen that has drawn both fascination and criticism from his growing audience. “A lot of it is pharmacology,” he explained, describing his use of testosterone replacement and what he calls a GLP-1 agonist.
He continued: “I use something similar to Ozempic called retatrutide. That’s a peptide that basically suppresses my appetite, making it difficult to eat.”
The influencer defended his approach by emphasizing the importance of body composition in physical appearance. “Being lean is about 70% of what you could accomplish in terms of looksmaxxing,” he stated, framing the medication as a practical tool rather than a shortcut. His methodology extends beyond appetite suppression to include testosterone management and hair loss prevention, creating what he describes as a systematic approach to optimization.
Critics have questioned whether such public endorsement of such interventions is appropriate for someone with significant influence over young men. However, Clavicular maintains that his transparency serves an educational purpose.
“These things are meant to disrupt this process” in modern society, he said, referring to natural hormone production. “My entire mentality is just don’t try to fight it with doing these carnivore diets and wearing cotton clothes. Just get off the entire thing and use exogenous hormones.”
Clavicular has emerged as a leading voice for looksmaxxing in the recent years. Unlike traditional fitness influencers who emphasize natural methods, he advocates for what he calls taking things “to its logical conclusion” through biohacking and pharma assistance.
During the interview, Clavicular pushed back against characterizations that he recklessly promotes these. He emphasized dose-dependency and distinction from bodybuilding culture.
“When you’re talking about TRT or slightly above that, that’s not comparable with bodybuilders who are using about 10 or 20 times the dosage,” he noted, attempting to distance his recommendations from more extreme practices.
During the conversation, he also suggested that for many young men facing difficult economic prospects, investing in physical appearance through pharma means that they offer better returns than traditional paths like higher education. This perspective resonates with his predominantly male audience, who he claims feel “understood by my messaging” about struggles that lack adequate representation.
